StemCells Inc. has started a trial — the first ever using neural stem cells — in patients with chronic spinal cord injury.
The Palo Alto company (NASDAQ: STEM) said its Phase I/II trial will consist of 12 patients with chest-level spinal cord injury receiving direct transplants of human neural stem cells into their spinal cords.
No comments:
Post a Comment